Vikas S. Ostwal, MD, discusses data for trastuzumab emtansine (T-DM1) as second-line therapy in patients with HER2-positive advanced biliary tract cancers.
Vikas S. Ostwal, MD
Advertisement
Articles by Vikas S. Ostwal, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
2
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
3
FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma
4
FDA Grants Breakthrough Therapy and Fast Track Status to 68Ga-NYM096 in ccRCC
5